PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-117.41%
Both yoy net incomes decline, with VET at -17.60%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-3.65%
Both reduce yoy D&A, with VET at -9.43%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-300.00%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-34.78%
Negative yoy SBC while VET is 280.57%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-2135.29%
Negative yoy working capital usage while VET is 27.71%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-1001.95%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
141.16%
AP growth of 141.16% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-2135.29%
Negative yoy usage while VET is 27.71%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
33766.67%
Well above VET's 98.09%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-7.43%
Negative yoy CFO while VET is 36.23%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-7.13%
Negative yoy CapEx while VET is 41.47%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-1293.71%
Negative yoy acquisition while VET stands at 75.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
200.00%
We have some outflow growth while VET is negative at -148.37%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-2.96%
We reduce yoy invests while VET stands at 18.20%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-6900.00%
Both yoy lines negative, with VET at -4614.34%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
35.69%
Buyback growth of 35.69% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.